BioNTech, Cuts

BioNTech Cuts IT Staff in Mainz While Roche Picks Up the R&D Tab From 2027

Published on 11/17/2026 at 18:41 | Editorial boerse-global.de
BioNTech cut a low three-digit number of jobs, mainly IT in Mainz, and will shift future Roche/Genentech R&D costs to Roche from 2027.
BioNTech Cuts IT Staff in Mainz While Roche Picks Up the R&D Tab From 2027 Illustration mit AI erstellt.

BioNTech is shrinking its payroll at home while rearranging who pays for its cancer research abroad. The two moves landed within days of each other in early November, and together they sketch a company trying to look leaner without slowing its pipeline.

A low three-digit number of positions has already been eliminated, concentrated in IT at the Mainz headquarters, according to media reports dated 11 November. Roughly 40 more job cuts are planned, mainly in Mainz. Separately, on 3 November, the company said it had exercised an option in its collaboration with Roche/Genentech: future research and development costs are to be allocated to Roche/Genentech in principle from 1 January 2027. BioNTech retains the right to licensing payments should development and commercialization succeed.

The ongoing PDAC study will continue as planned, the company said. The cost reallocation applies to the joint program with Roche/Genentech.

A Quarter That Cuts Both Ways

The third quarter of 2026 brought revenue of EUR 1,289.2 million and a net profit of EUR 184.5 million. Over the first nine months of 2026, revenue reached EUR 1.51 billion, but the bottom line showed a net loss of EUR 1.17 billion. BioNTech attributed the lower revenue chiefly to the expectedly weaker demand for its COVID-19 vaccines.

Should investors sell immediately? Or is it worth buying BioNTech?

Guidance for adjusted research and development spending, as well as for sales and administrative costs, was left unchanged. What did move was the revenue floor for the full year 2026: the lower bound was raised to a range of EUR 1,700 million to EUR 1,900 million, with the upper end held steady.

$205 Million for a Faster Lane

Also in November, BioNTech agreed to acquire a Priority Review Voucher from the US Food and Drug Administration via Scholar Rock, at a cash purchase price of $205 million. The voucher is intended for a future marketing application from a late-stage oncology asset in BioNTech's pipeline. Closing is subject to customary conditions, including antitrust clearance under the HSR process.

The voucher purchase is no guarantee of a later approval. It does, however, mark a concrete priority in how capital is deployed. Cutting staff and funding development are not mutually exclusive at BioNTech — they have to be judged together.

What the Two Sides Add Up To

A smaller workforce on its own does not make a company more valuable, and a single quarterly profit does not answer the question of what cost base fits the future. The completed reductions and the additional plans are distinct matters, and the IT focus does not yet describe the consequences for the company as a whole.

The strategic logic has to be measured at the seam where the two sides meet: an appropriately sized organization and targeted investment in oncology. Fewer positions alone are not progress. Neither is an expensive development step on its own.

Ad

BioNTech Stock: New Analysis - 17 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

Disclaimer...
en | US09075V1026 | BIONTECH | boerse | 70528256 |